Motor and nonmotor symptoms significantly worsened in the COVID‐19 group, requiring therapy adjustment in one‐third of cases. Clinical deterioration was explained by both infection‐related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, while none experienced autonomic failure.
Read more in Movement Disorders 2020 Aug. Vol. 35(8); 1287-1292
Copyright © 2023 Parkinson's Europe. All Rights Reserved